Eli Lilly in licensing deal with CSL for clazakizumab
Source: SeekingAlpha
2026-02-17 17:00:50 ET
More on Eli Lilly
- Eli Lilly: Positives Outweigh The Concerns
- Eli Lilly and Company 2025 Q4 - Results - Earnings Call Presentation
- Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript
- Eli Lilly posts late-stage trial win for Retevmo as adjuvant lung cancer therapy
- Renaissance Technologies adds Amazon, Lilly, exits Meta, among top Q4 trades
Read the full article on Seeking Alpha
For further details see:
Eli Lilly in licensing deal with CSL for clazakizumab
CSL Ltd. ADR
NASDAQ: CSLLY
CSLLY Trading
-1.46% G/L:
$24.91 Last:
12,881 Volume:
$25 Open:
CSLLY Latest News
March 09, 2026 11:01:00 am
CSL announces expansion of Illinois plasma therapy manufacturing facility
March 06, 2026 09:00:00 am
Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract
January 27, 2026 02:06:00 pm
Deutsche Bank Appointed as Successor Depositary Bank for the American Depositary Receipt Program of CSL Limited
CSLLY Stock Data
$59,010,931,430
958,728,992
N/A
5
N/A
Biotechnology & Life Sciences
Healthcare
AU
Prakville Victoria Austra
